CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
51.01
1.47%
Market Trading Hours* (UTC) Opens on Monday at 08:00

Mon - Thu: 08:00 - 16:30

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.16
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.022096 %
Charges from full value of position ($-4.20)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.022096%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.000126 %
Charges from full value of position ($-0.02)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.000126%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency EUR
Margin 5%
Stock exchange Italy
Commission on trade 0%

*Information provided by Capital.com

Recordati Industria Chimica e Farmaceutica SpA ESG Risk Ratings

High Medium Low Negligible

‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly

More ESG coverage

Key Stats
Prev. Close* 51.77
Open* 51.59
1-Year Change* 29.59%
Day's Range* 51.01 - 51.59
52 wk Range 37.78-51.18
Average Volume (10 days) 279.20K
Average Volume (3 months) 4.94M
Market Cap 10.41B
P/E Ratio 27.41
Shares Outstanding 205.53M
Revenue 2.03B
EPS 1.82
Dividend (Yield %) 2.34987
Beta 0.28
Next Earnings Date Feb 19, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 51.01 -0.64 -1.24% 51.65 51.65 50.97
Mar 27, 2024 51.77 0.52 1.01% 51.25 52.09 51.25
Mar 26, 2024 51.35 -0.60 -1.15% 51.95 52.01 51.05
Mar 25, 2024 52.11 0.06 0.12% 52.05 52.37 51.85
Mar 22, 2024 52.17 1.06 2.07% 51.11 52.43 51.07
Mar 21, 2024 51.45 0.30 0.59% 51.15 51.53 51.05
Mar 20, 2024 50.97 -0.06 -0.12% 51.03 51.45 50.77
Mar 19, 2024 51.31 -0.40 -0.77% 51.71 51.75 50.35
Mar 18, 2024 51.81 -0.94 -1.78% 52.75 52.99 51.75
Mar 15, 2024 52.63 -0.24 -0.45% 52.87 53.17 52.59
Mar 14, 2024 52.77 0.02 0.04% 52.75 53.09 52.47
Mar 13, 2024 52.91 -0.16 -0.30% 53.07 53.31 52.65
Mar 12, 2024 52.89 0.20 0.38% 52.69 52.95 52.21
Mar 11, 2024 52.61 0.18 0.34% 52.43 52.85 52.37
Mar 8, 2024 52.69 0.22 0.42% 52.47 52.95 52.21
Mar 7, 2024 52.53 0.82 1.59% 51.71 52.71 51.71
Mar 6, 2024 51.81 0.38 0.74% 51.43 51.91 51.19
Mar 5, 2024 51.65 0.34 0.66% 51.31 51.93 51.25
Mar 4, 2024 51.63 -0.34 -0.65% 51.97 52.09 51.59
Mar 1, 2024 52.03 0.46 0.89% 51.57 52.07 51.01

Recordati SPA Events

Time (UTC) Country Event
Thursday, May 9, 2024

Time (UTC)

10:59

Country

IT

Event

Q1 2024 Recordati Industria Chimica e Farmaceutica SpA Earnings Release
Q1 2024 Recordati Industria Chimica e Farmaceutica SpA Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1853.31 1580.07 1448.87 1481.85 1352.23
Revenue 1853.31 1580.07 1448.87 1481.85 1352.23
Cost of Revenue, Total 566.737 427.727 406.831 436.901 395.569
Gross Profit 1286.57 1152.35 1042.04 1044.95 956.666
Total Operating Expense 1411.47 1089.88 979.851 1016.58 910.016
Selling/General/Admin. Expenses, Total 572.158 480.889 421.857 445.586 401.219
Research & Development 220.102 166.138 146.236 77.081 67.093
Unusual Expense (Income) 52.975 14.478 4.927 0.264 3.535
Operating Income 441.832 490.19 469.016 465.266 442.219
Interest Income (Expense), Net Non-Operating -40.252 -26.718 -13.203 -20.616 -17.977
Other, Net -0.145 -0.123 -0.157 -0.506 -6.307
Net Income Before Taxes 401.435 463.349 455.656 444.144 417.935
Net Income After Taxes 312.336 385.966 355.027 368.866 312.422
Minority Interest 0 0 -0.043 -0.041 -0.046
Net Income Before Extra. Items 312.336 385.966 354.984 368.825 312.376
Net Income 312.336 385.966 354.984 368.825 312.376
Income Available to Common Excl. Extra. Items 312.336 385.966 354.984 368.825 312.376
Income Available to Common Incl. Extra. Items 312.336 385.966 354.984 368.825 312.376
Dilution Adjustment
Diluted Net Income 312.336 385.966 354.984 368.825 312.376
Diluted Weighted Average Shares 205.582 209.082 209.06 209.084 209.087
Diluted EPS Excluding Extraordinary Items 1.51928 1.846 1.698 1.764 1.494
Dividends per Share - Common Stock Primary Issue 1.15 1.1 1.05 1 0.92
Diluted Normalized EPS 1.57912 1.89642 1.7131 1.76505 1.50664
Depreciation / Amortization 52.6 42.6
Other Operating Expenses, Total -0.497 0.652 0 4.15
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 492.909 551.363 475.765 485.052 473.109
Revenue 492.909 551.363 475.765 485.052 473.109
Cost of Revenue, Total 148.3 163.654 143.933 154.924 152.402
Gross Profit 344.609 387.709 331.832 330.128 320.707
Total Operating Expense 351.991 377.95 384.224 362.353 376.788
Selling/General/Admin. Expenses, Total 145.206 150.429 160.39 144.952 145.083
Research & Development 58.585 60.458 64.402 56.367 55.664
Unusual Expense (Income) 1.095 1.937 12.992 6.715 23.978
Other Operating Expenses, Total -1.195 1.472 2.507 -0.605 -0.339
Operating Income 140.918 173.413 91.541 122.699 96.321
Interest Income (Expense), Net Non-Operating -11.898 -13.38 0.239 -7.103 -26.462
Other, Net -0.091 -0.092 -0.063 -0.028 -0.027
Net Income Before Taxes 128.929 159.941 91.717 115.568 69.832
Net Income After Taxes 103.617 123.954 70.878 90.053 54.685
Minority Interest 0 0 0 0 0
Net Income Before Extra. Items 103.617 123.954 70.878 90.053 54.685
Net Income 103.617 123.954 70.878 90.053 54.685
Income Available to Common Excl. Extra. Items 103.617 123.954 70.878 90.053 54.685
Income Available to Common Incl. Extra. Items 103.617 123.954 70.878 90.053 54.685
Diluted Net Income 103.617 123.954 70.878 90.053 54.685
Diluted Weighted Average Shares 205.421 209.029 205.417 205.602 208.895
Diluted EPS Excluding Extraordinary Items 0.50441 0.593 0.34504 0.438 0.26178
Dividends per Share - Common Stock Primary Issue 0 0 0.6 0 0.55
Diluted Normalized EPS 0.55119 0.6427 0.36713 0.4423 0.29466
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 1173.62 850.101 772.951 809.35 699.931
Cash and Short Term Investments 284.734 244.578 188.23 187.923 198.036
Cash 162.636 230.924 175.227 141.384 172.421
Cash & Equivalents 122.098 13.654 13.003 46.539 25.615
Total Receivables, Net 424.062 350.335 313.859 374.328 281.276
Accounts Receivable - Trade, Net 361.898 307.778 268.897 296.961 245.742
Total Inventory 424.08 228.732 251.252 226.885 206.084
Prepaid Expenses 17.138 15.307 12.574 10.265 8.121
Other Current Assets, Total 23.603 11.149 7.036 9.949 6.414
Total Assets 3998.82 2816.2 2711.65 2808.93 2161.26
Property/Plant/Equipment, Total - Net 159.184 131.12 133.25 133.342 103.582
Property/Plant/Equipment, Total - Gross 521.17 462.825 453.036 437.716 387.858
Accumulated Depreciation, Total -361.986 -331.705 -319.786 -304.374 -284.276
Goodwill, Net 780.057 553.209 562.116 577.973 577.786
Intangibles, Net 1758.17 1138.79 1115.81 1161.76 672.106
Long Term Investments 28.871 34.124 45.581 38.566 20.773
Other Long Term Assets, Total 98.921 108.859 81.945 87.939 87.087
Total Current Liabilities 923.743 626.416 578.464 586.754 490.742
Accounts Payable 224.703 177.925 132.096 175.481 165.02
Accrued Expenses 82.96 56.191 39.649 45.267 42.289
Notes Payable/Short Term Debt 83.425 8.657 12.567 13.392 16.905
Current Port. of LT Debt/Capital Leases 291.546 223.061 270.254 149.817 130.583
Other Current Liabilities, Total 241.109 160.582 123.898 202.797 135.945
Total Liabilities 2452.57 1434.57 1435.67 1610.35 1197.87
Total Long Term Debt 1341.55 760.473 778.238 937.344 640.647
Long Term Debt 1319.98 745.382 760.587 937.344 640.647
Deferred Income Tax 167.865 26.675 41.219 43.172 43.486
Minority Interest 0 0 0.277 0.234 0.193
Other Liabilities, Total 19.418 21.01 37.473 42.849 22.804
Total Equity 1546.25 1381.62 1275.98 1198.58 963.393
Common Stock 26.141 26.141 26.141 26.141 26.141
Additional Paid-In Capital 83.719 83.719 83.719 83.719 83.719
Retained Earnings (Accumulated Deficit) 1785.72 1612.81 1473.6 1334.42 1161.69
Treasury Stock - Common -149.559 -126.981 -87.516 -93.48 -145.608
Other Equity, Total -199.769 -214.06 -219.962 -152.223 -162.545
Total Liabilities & Shareholders’ Equity 3998.82 2816.2 2711.65 2808.93 2161.26
Total Common Shares Outstanding 205.441 205.911 206.296 204.959 204.379
Capital Lease Obligations 21.571 15.091 17.651
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 1223.43 1449.1 1191.21 1173.62 1242.55
Cash and Short Term Investments 302.28 528.568 231.294 284.734 346.609
Cash & Equivalents 302.28 528.568 231.294 284.734 346.609
Total Receivables, Net 477.028 452.948 488.17 425.813 443.062
Accounts Receivable - Trade, Net 421.755 404.2 439.594 361.898 393.437
Total Inventory 401.645 425.715 427.664 424.08 403.981
Other Current Assets, Total 42.478 41.867 44.08 23.603 48.9
Total Assets 4231.56 4208.39 3982.07 3998.82 3977.85
Property/Plant/Equipment, Total - Net 172.976 166.251 162.311 159.184 147.226
Property/Plant/Equipment, Total - Gross 545.511 577.44 528.919 521.17 504.681
Accumulated Depreciation, Total -372.535 -411.189 -366.608 -361.986 -357.455
Goodwill, Net 778.655 766.98 784.537 780.057 707.709
Intangibles, Net 1939.79 1710.55 1725.66 1758.17 1714.51
Long Term Investments 20.22 24.513 24.48 28.871 26.972
Other Long Term Assets, Total 96.492 90.998 93.88 98.921 138.884
Total Current Liabilities 955.639 950.157 880.962 923.743 778.04
Accounts Payable 252.826 248.015 246.983 224.703 219.638
Notes Payable/Short Term Debt 41.652 15.926 23.232 83.425 5.656
Current Port. of LT Debt/Capital Leases 396.632 378.214 293.631 291.546 290.496
Other Current Liabilities, Total 264.529 308.002 317.116 324.069 262.25
Total Liabilities 2506.55 2599.16 2327.6 2452.57 2367.38
Total Long Term Debt 1377.51 1470.52 1263.98 1341.55 1404.18
Long Term Debt 1349.12 1441.35 1241.75 1319.98 1389.79
Deferred Income Tax 154.255 159.213 163.737 167.865 163.776
Minority Interest 0 0 0 0 0
Other Liabilities, Total 19.141 19.267 18.924 19.418 21.39
Total Equity 1725.01 1609.22 1654.47 1546.25 1610.47
Common Stock 26.141 26.141 26.141 26.141 26.141
Additional Paid-In Capital 83.719 83.719 83.719 83.719 83.719
Retained Earnings (Accumulated Deficit) 1996.82 1903.48 1920.3 1785.72 1761.87
Treasury Stock - Common -126.986 -145.52 -152.695 -149.559 -149.782
Other Equity, Total -254.681 -258.6 -222.995 -199.769 -111.476
Total Liabilities & Shareholders’ Equity 4231.56 4208.39 3982.07 3998.82 3977.85
Total Common Shares Outstanding 205.53 205.535 205.358 205.441 205.459
Prepaid Expenses 15.387
Capital Lease Obligations 28.389 29.172 22.233 21.571 14.387
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 312.336 385.966 355.027 368.866 312.422
Cash From Operating Activities 461.691 492.129 403.575 318.7 357.838
Cash From Operating Activities 27.289 25.294 25.355 25.17 13.901
Amortization 98.467 72.291 68.317 53.078 42.959
Deferred Taxes -6.637
Non-Cash Items 209.716 113.194 124.979 102.747 4.697
Changes in Working Capital -186.117 -104.616 -170.103 -231.161 -9.504
Cash From Investing Activities -767.124 -87.499 -131.555 -441.209 -231.778
Capital Expenditures -96.339 -87.36 -131.678 -443.288 -19.362
Other Investing Cash Flow Items, Total -670.785 -0.139 0.123 2.079 -212.416
Cash From Financing Activities 341.277 -355.943 -264.288 109.526 -224.688
Financing Cash Flow Items 1.74 -2.19 0.439
Total Cash Dividends Paid -230.602 -216.742 -212.718 -190.916 -178.887
Issuance (Retirement) of Stock, Net -38.619 -59.308 -12.17 26.187 -149.552
Issuance (Retirement) of Debt, Net 610.498 -79.893 -41.14 276.445 103.312
Net Change in Cash 40.156 56.348 0.307 -10.113 -104.369
Foreign Exchange Effects 4.312 7.661 -7.425 2.87 -5.741
Cash Taxes Paid 89.764 91.646 65.272 140.14
Cash Interest Paid 20.093 18.279 18.699 17.597
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 123.954 312.336 241.458 151.405 96.72
Cash From Operating Activities 107.923 461.691 361.692 226.113 113.431
Cash From Operating Activities 7.004 27.289 19.675 12.895 6.016
Amortization 27.188 98.467 70.563 44.289 18.635
Non-Cash Items 66.727 209.716 145.296 97.032 35.714
Cash Taxes Paid 12.33 89.764 55.992 42.515 10.653
Cash Interest Paid 17.818 20.093 14.385 8.569 2.344
Changes in Working Capital -116.95 -186.117 -115.3 -79.508 -43.654
Cash From Investing Activities -14.006 -767.124 -736.385 -715.11 -722.27
Capital Expenditures -17.557 -96.339 -83.684 -62.222 -15.599
Other Investing Cash Flow Items, Total 3.551 -670.785 -652.701 -652.888 -706.671
Cash From Financing Activities -144.562 341.277 452.436 601.573 571.438
Total Cash Dividends Paid -6.139 -230.602 -120.017 -119.544 -6.219
Issuance (Retirement) of Stock, Net -4.075 -38.619 -29.989 -16.634 -18.383
Issuance (Retirement) of Debt, Net -134.348 610.498 602.442 737.751 596.04
Foreign Exchange Effects -2.795 4.312 24.288 16.608 1.018
Net Change in Cash -53.44 40.156 102.031 129.184 -36.383

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Recordati Company profile

About Recordati Industria Chimica e Farma SpA

Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Recordati Industria Chimica e Farma SpA revenues increased 9% to EUR1.58B. Net income increased 9% to EUR386M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share increased from EUR1.05 to EUR1.10. Basic Earnings per Share excluding Extraordinary Items increased from EUR1.73 to EUR1.87.

Industry: Pharmaceuticals (NEC)

Via M. Civitali, 1
MILANO
MILANO 20148
IT

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,577.75 Price
-0.440% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.63 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading